Revolution Medicines launches Phase 3 trial of zoldonrasib for RAS G12D lung cancer
Revolution Medicines (RVMD) began enrolling patients in the global Phase 3 RASolve 308 study, testing its investigational RAS(ON) G12D‑selective inhibitor zoldonrasib together with pembrolizumab and platinum‑based chemotherapy. The trial targets adults with metastatic non‑squamous non‑small cell lung cancer harboring the RAS G12D mutation, a subgroup that represents about 4 % of NSCLC cases and has no approved targeted therapy. Progression‑free survival is the primary endpoint, with overall survival and safety among the secondary measures. The company reported that shares rose 6.90 % to $194.71 following the announcement.
Why it matters
The study could provide the first approved targeted treatment for RAS G12D NSCLC, potentially expanding the market for Revolution Medicines and influencing its valuation; the immediate share price gain reflects investor optimism about the trial’s prospects.
Key facts
- 1Revolution Medicines started treating patients in the global Phase 3 RASolve 308 trial of zoldonrasib. investing.com
- 2The trial evaluates zoldonrasib in combination with pembrolizumab and platinum‑based chemotherapy as first‑line therapy. investing.com
- 3The patient population represents approximately 4 % of non‑small cell lung cancer cases. investing.com
- 4The primary endpoint of the study is progression‑free survival. finance.yahoo.com
- 5Secondary endpoints include overall survival, objective response rate, duration of response, safety, tolerability and patient‑reported outcomes. finance.yahoo.com
- 6Revolution Medicines shares were up 6.90 % at $194.71 at the time of publication. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.